

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MINGYUAN MEDICARE DEVELOPMENT COMPANY LIMITED

銘源醫療發展有限公司*

(incorporated in Bermuda with limited liability)

(Stock Code: 0233)

EXCLUSIVE DISTRIBUTION AGREEMENT SIGNED WITH LUMINEX CORPORATION

The Board is pleased to announce that the Company has been appointed by Luminex as the exclusive distributor of a series of newborn screening products for diagnosis of genetic disorders in China and Hong Kong.

The Board of Directors (the “Board”) of Mingyuan Medicare Development Company Limited (the “Company”) is pleased to announce that the Company has signed a distribution agreement (“Agreement”) with Luminex Corporation (“Luminex”), a Delaware corporation listed on NASDAQ, on 2 October 2008. Under the Agreement, the Company will serve as the exclusive distributor of a series of newborn screening products (“NSPs”) for the diagnosis of genetic diseases in China and Hong Kong. The NSPs are developed by Luminex utilizing its proprietary multiplexing xMAP technology.

Genetic disorders such as phenylketonuria (commonly known as PKU), congenital hypothyroidism (commonly known as CH), congenital adrenal hyperplasia (commonly known as CAH) and glucose-6-phosphate dehydrogenase (commonly known as G6PD) deficiency affect the development of thousands of newborns each year in China. If these disorders are not found and detected early, the affected newborns may experience significant cognitive development delays and ongoing health complications. There are about 20 million newborns each year in China and newborn screening of genetic disorders are mandated by the Chinese government. When genetic disorders are detected in babies early, doctors can monitor the babies for health complication and begin treatments quickly. This will improve the infants quality of life and life expectancy. Instead of detecting each genetic disorder one at a time, Luminex’s proprietary multiplexing xMAP technology can simultaneously analyze up to 100 unique assays within a single sample, making large scale screening more efficient, accurate and less costly.

Luminex develops, manufactures and markets innovative biological testing technologies with applications throughout the life science and diagnostic industries. Luminex’s proprietary multiplexing xMap technology delivers fast, accurate and cost effective bioassay results and is sold worldwide to leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies.

Besides the Agreements, the Company is also working closely with Luminex on development of diagnostic products for cancer and cardiac-related diseases.

By order of the Board
Mingyuan Medicare Development Company Limited
銘源醫療發展有限公司*
Chien Hoe Yong, Henry
CEO and Executive Director

Hong Kong, 9 October 2008

As at the date of this announcement, the executive directors are Mr. Yao Yuan (Executive Chairman), Mr. Chien Hoe Yong, Henry (CEO), Mr. Iu Chung, Mr. Hu Jun, and Mr. Yu Ti Jun; non-executive directors are Mr. Yang Zhen Hua and Mr. Ma Yong Wei; the independent non-executive directors are Dr. Lam Lee G., Mr. Hu Jin Hua and Mr. Lee Sze Ho, Henry.

* *For identification purposes only*